Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study
LYSA 研究通过对 1280 例参与临床试验的套细胞淋巴瘤患者进行分析，验证了 POD24 作为套细胞淋巴瘤早期预后不良的可靠临床指标的有效性。
期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-025-01241-9
Sarkozy, Clémentine; Chartier, Loïc; Ribrag, Vincent; Gressin, Remy; Geisler, Christian H; Kluin-Nelemans, Hanneke C; Thieblemont, Catherine; Morschhauser, Franck; Lemonnier, François; Safar, Violaine; Tessoulin, Benoît; Oberic, Lucie; Damaj, Ghandi; Ghesquières, Hervé; Bouabdallah, Krimo; Casasnovas, René Olivier; Houot, Roch; Klapper, Wolfram; Burroni, Barbara; Pott, Christiane; Delfau-Larue, Marie-Hélène; Macintyre, Elizabeth; Callanan, Mary; Jerkeman, Mats; Unterhalt, Michael; Hoster, Eva; Dreyling, Martin; Le Gouill, Steven; Hermine, Olivier; Cheminant, Morgane
